CliffBio
biologic

Tremfya

guselkumab

Loss of exclusivityJanuary 2031projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameTremfya
Active ingredientguselkumab
Strength100MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2019
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tremfya patent cliff — loss of exclusivity January 2031 | CliffBio